Saber-Ayad, Maha;
Hammoudeh, Sarah;
Abu-Gharbieh, Eman;
Hamoudi, Rifat;
Tarazi, Hamadeh;
Al-Tel, Taleb H;
Hamid, Qutayba;
(2021)
Current Status of Baricitinib as a Repurposed Therapy for COVID-19.
Pharmaceuticals
, 14
(7)
, Article 680. 10.3390/ph14070680.
Preview |
Text
Current Status of Baricitinib as a Repurposed Therapy for COVID-19. .pdf - Published Version Download (1MB) | Preview |
Abstract
The emergence of the COVID-19 pandemic has mandated the instant (re)search for potential drug candidates. In response to the unprecedented situation, it was recognized early that repurposing of available drugs in the market could timely save lives, by skipping the lengthy phases of preclinical and initial safety studies. BenevolentAI’s large knowledge graph repository of structured medical information suggested baricitinib, a Janus-associated kinase inhibitor, as a potential repurposed medicine with a dual mechanism; hindering SARS-CoV2 entry and combatting the cytokine storm; the leading cause of mortality in COVID-19. However, the recently-published Adaptive COVID-19 Treatment Trial-2 (ACTT-2) positioned baricitinib only in combination with remdesivir for treatment of a specific category of COVID-19 patients, whereas the drug is not recommended to be used alone except in clinical trials. The increased pace of data output in all life sciences fields has changed our understanding of data processing and manipulation. For the purpose of drug design, development, or repurposing, the integration of different disciplines of life sciences is highly recommended to achieve the ultimate benefit of using new technologies to mine BIG data, however, the final say remains to be concluded after the drug is used in clinical practice. This review demonstrates different bioinformatics, chemical, pharmacological, and clinical aspects of baricitinib to highlight the repurposing journey of the drug and evaluates its placement in the current guidelines for COVID-19 treatment.
| Type: | Article |
|---|---|
| Title: | Current Status of Baricitinib as a Repurposed Therapy for COVID-19 |
| Location: | Switzerland |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3390/ph14070680 |
| Publisher version: | https://doi.org/10.3390/ph14070680 |
| Language: | English |
| Additional information: | This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited |
| Keywords: | Bioinformatics; transcriptomics; gene expression; baricitinib; JAK inhibitors; COVID-19; clinical trial |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10148939 |
Archive Staff Only
 |
View Item |
